These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3155882)

  • 1. Ly-1+2- suppressor T cells inhibit the expression of passively transferred antitumor immunity by suppressing the generation of cytolytic T cells.
    Mills CD; North RJ
    Transplantation; 1985 Feb; 39(2):202-8. PubMed ID: 3155882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.
    Mills CD; North RJ
    J Exp Med; 1983 May; 157(5):1448-60. PubMed ID: 6189937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.
    North RJ; Dye ES
    Immunology; 1985 Jan; 54(1):47-56. PubMed ID: 3156088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity.
    DiGiacomo A; North RJ
    J Exp Med; 1986 Oct; 164(4):1179-92. PubMed ID: 2944983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.
    North RJ; Bursuker I
    J Exp Med; 1984 May; 159(5):1295-311. PubMed ID: 6232335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
    Dye ES
    J Immunol; 1986 Feb; 136(4):1510-5. PubMed ID: 3080526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic significance of concomitant antitumor immunity. I. LY-1-2+ T cells from mice with a progressive tumor can cause regression of an established tumor in gamma-irradiated recipients.
    North RJ
    Cancer Immunol Immunother; 1984; 18(2):69-74. PubMed ID: 6334549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.
    Dye ES; North RJ
    J Leukoc Biol; 1984 Jul; 36(1):27-37. PubMed ID: 6234371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors.
    Bursuker I; North RJ
    Cancer Immunol Immunother; 1985; 19(3):215-8. PubMed ID: 3159472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic significance of concomitant antitumor immunity. II. Passive transfer of concomitant immunity with Ly-1+2- T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression.
    North RJ
    Cancer Immunol Immunother; 1984; 18(2):75-9. PubMed ID: 6391656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity.
    Bursuker I; North RJ
    J Exp Med; 1984 May; 159(5):1312-21. PubMed ID: 6232336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two distinct mechanisms regulate the in vivo generation of cytotoxic T cells.
    Sy MS; Lee SH; Tsurufuji M; Rock KL; Benacerraf B; Finberg R
    J Exp Med; 1982 Sep; 156(3):918-23. PubMed ID: 6213734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune response of the mouse to lymphocytic choriomeningitis virus. V. High numbers of cytolytic T lymphocytes are generated in the spleen during acute infection.
    Moskophidis D; Assmann-Wischer U; Simon MM; Lehmann-Grube F
    Eur J Immunol; 1987 Jul; 17(7):937-42. PubMed ID: 2886344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression.
    Dye ES; North RJ
    Transplantation; 1984 Jun; 37(6):600-5. PubMed ID: 6427998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro T cell-mediated killing of Pseudomonas aeruginosa. V. Generation of bactericidal T cells in nonresponder mice.
    Powderly WG; Pier GB; Markham RB
    J Immunol; 1987 Apr; 138(7):2272-7. PubMed ID: 2951437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the phenotypes of cells mediating anti-tumour immunity at various stages of tumour progression in mice.
    Dent LA; Spencer LK; Attridge S; Finlay-Jones JJ
    Immunol Cell Biol; 1989 Dec; 67 ( Pt 6)():403-12. PubMed ID: 2696727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoregulatory circuits which modulate responsiveness to suppressor cell signals: characterization of an effector cell in the contrasuppressor circuit.
    Green DR; Eardley DD; Kimura A; Murphy DB; Yamauchi K; Gershon RK
    Eur J Immunol; 1981 Dec; 11(12):973-80. PubMed ID: 6459945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of suppression in the transfer of contact sensitivity. Analysis of an I-J+ molecule required for Ly2 suppressor cell activity.
    Ptak W; Gershon RK; Flood PM
    J Exp Med; 1983 Dec; 158(6):1822-35. PubMed ID: 6196432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.